Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Edaravone Dexcamphorol on Blood–Brain Barrier in Acute Cerebral Infarction
ChiCTR2300077616Phase 4Recruiting
- Sponsor
- Jiangjin Central Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of edaravone dexcamphorol and edaravone in ischemic stroke and cerebrovascular disease (2 arms), sponsored by Jiangjin Central Hospital. Primary endpoints: Ktrans value at 14 days and Ki/c value at 90 days. Started Nov 2023; status: recruiting.
02
Drugs
edaravone dexcamphoroledaravone
03
Conditions
ischemic strokecerebrovascular disease
Beyond the preview
Go deeper on ChiCTR2300077616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077616.